NCT01565902View on ClinicalTrials.gov

Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Hepatic Impairment
Interventions
DRUG

BAF312

Treatment with a single oral dose of 0.25 mg BAF312

Trial Locations (3)

1076

Novartis Investigative Site, Budapest

8230

Novartis Investigative Site, Balatonfüred

115419

Novartis Investigative Site, Moscow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY